The size of the Antifungal Drugs Market in the Asia Pacific has been estimated at USD 2.09 billion in 2020. This value is further forecasted to be growing at a CAGR of 4.1% and worth USD 2.55 billion by 2025. In the following few years, the market is projected to grow enormously with the growing global population.
Antifungal drugs are used to cure fungal infections which are usually caused by the unclean, unhygienic and damp environments. Fungal infections are the invasion of epithelial tissue by microscopic organisms. Systemic fungal infections are caused by indigestion or inhalation of fungus spores and cause fungal pneumonia and opportunistic fungus causes diseases like candidiasis, meningitis, mucormycosis, etc. Most of the fungal infections and fungal diseases are generally non-lethal but they are very uncomfortable to live with. Commonly occurring fungal infections are responsible for the rise of the antifungal drugs market. Antifungal drugs work through various mechanisms such as inhibiting cell wall formation, cell membrane disruption, and cell division.
The major factors driving the market are rising awareness of fungal infections with the increasing incidence of antifungal infections all over the world, rising government and corporate funding in the industry. Further, more and more development of public-private partnerships in the pharmaceutical industry and the rising popularity of over-the-counter antifungal drugs for dermal infections are vastly responsible for increasing the market size. Also, the increase of population with weak, in whom the occurrence of fungal infections is much more than average, will drive the market. Existing high penetration of conventional drugs used for the treatment of fungal infections is restraining the Asia-Pacific Antifungal drugs market’s growth.
The key challenges faced by the Asia-Pacific Antifungal drugs market are the cost of drugs and their effectiveness in treatments. As many countries in Asia-Pacific are having emerging economies, the antifungal drug market in the region is going to grow fastest.
This research report on the APAC Antifungal Drugs Market has been segmented and sub-segmented into the following categories:
By Drug Type:
By Therapeutic Indications:
By Application:
By Country:
Geographically, the Antifungal drugs market in Asia-Pacific is the fastest-growing followed by Latin America. India's antifungal drug market is the fastest growing in the Asia-pacific region.
Some of the notable players operating in the Asia Pacific Antifungal drugs market are Alternaria, Pfizer, Novartis, Sanofi-Aventis, Merck & Co., Asperqillus, Kramer Laboratories, Bayer Healthcare, Enzon Pharmaceuticals, Glaxosmithkline Gilead and Abbott Laboratories.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Echinocandins
5.1.2 Azoles
5.1.3 Polyenes
5.1.4 Allylamines
5.1.5 Others
5.2 By Therapeutic Indications
5.2.1 Aspergillosis
5.2.2 Dermatophytosis
5.2.3 Candidiasis
5.2.4 Others
5.3 By Application
5.3.1 Powders
5.3.2 Ointments
5.3.5 Drugs
5.3.4 Pastes
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Alternaria
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer
8.3 Novartis
8.4 Sanofi-Aventis
8.5 Merck & Co.
8.6 Asperqillus
8.7 Kramer Laboratories
8.8 Bayer Healthcare
8.9 Enzon Pharmaceuticals
8.10 Glaxosmithkline Gilead
8.11 Abbott Laboratories
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
